Fig. 3

Kinetics of virus-specific B cell responses to SARS-CoV2 in COVID-19 Asymptomatic patients. Sample of a, b and f was from Asymptomatic (#6). a, b FACS plot examples of SARS-CoV2 S1- or S2- specific B cells and plasmablasts (CD19⁺CD20^-CD27^hiCD38^hi) cells’ percentage in early phase (0–3 days post hospitalization), acute phase (5–10 days post hospitalization), convalescent-phase, (more than 10 days after COVID-19 nucleic acid test shown negative) in the asymptomatic cohort. c, d Percentages of S1- or S2- specific B cells (c), summarized from (a), and plasmablasts cells (d), summarized from (b), in the asymptomatic cohort. e Kinetics of S1- and S2- specific IgG levels in asymptomatic patients’ serum, measured by ELISA. f FACS plot examples of cT_FH cells’ percentage of asymptomatic patients. g Percentages of cT_FH, summarized from (f). h Kinetics of CXCL13 level in asymptomatic patients’ serum, measured by ELISA. Bars represent the mean ± SEM. P values were calculated based on Bonferroni of one-way ANOVA analysis. ***p < 0.0001, **p < 0.001, and *p < 0.05